Elwood P. Armour

TL;DR: If true, hypofractionation or HDR regimens for prostate radiotherapy (with appropriate doses) should produce tumor control and late sequelae that are at least as good or even better than currently achieved, with the added possibility that early sequelae may be reduced.

TL;DR: The capability of the SARRP to deliver highly focal beams to multiple animal model systems provides new research opportunities that more realistically bridge laboratory research and clinical translation.

TL;DR: Pelvic EBRT interdigitated with transrectal ultrasound-guided real-time conformal HDR prostate brachytherapy boost is both a precise dose delivery system and a very effective treatment for unfavorable prostate cancer.

TL;DR: The heat sensitivity measurements point out the shortcomings of using data derived from rodent systems to predict clinical outcome of hyperthermia therapy, when compared to heat sensitive rodent cell lines.

TL;DR: Clinical results involving the application of ultrasonic hyperthermia alone, and in conjuction with chemotherapy and radiation in 215 patients are reported, with particular encouragement was the treatment of advanced primary breast cancer with ultrasound combined with chemotherapy, where the first seven patients exhibited a 100 percent overall response rate to therapy.